Together, our findings unveil a complex web of molecular alterations that may impact the therapeutic susceptibility of KRAS and EGFR-mutant non-Sq NSCLC across different ancestry groups and consequently may contribute to molecular underpinnings of cancer disparities. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.